Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373145 | 0.84 | GAA (0.45) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL4819904 | 0.84 | GAA (0.45) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL13681841 | 0.84 | GAA (0.45) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL10747370 | 0.83 | GAA (0.44) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL8917423 | 0.82 | CYP2D6 (0.56) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL9797359 | 0.82 | GAA (0.46) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL16329489 | 0.81 | KMT2A (0.43) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL19355183 | 0.81 | GAA (0.43) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL18283386 | 0.80 | GAA (0.49) | GAAKMT2AMEN1MGAMSI | |
| SCHEMBL20908046 | 0.80 | GAA (0.45) | GAAKMT2AMEN1MGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | Interface Biologics ,Inc. (CA) | 2011-04-21 | — | — | US | disclosed |
| WO-1995021262-A1 | PROCESS FOR SOLID PHASE GLYCOPEPTIDE SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5369017-A | Process for solid phase glycopeptide synthesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091508-A1 | OLIGOFLUORINATED CROSS-LINKED POLYMERS AND USES THEREOF | MACF1, PUF60, PFAS | GAA 1817/4885KMT2A 1963/4885MEN1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.